Structure-Based Search for Novel Antihypercholestrolemic Agents
Structure-Based Search for Novel Antihypercholestrolemic Agents
批准号:
7537300
负责人:
Sherin S Abdel-Meguid
金额:
$25.9万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-08-04 至 2010-04-30
关键词:
AccountingActive SitesAddressAdverse effectsAreaBiochemicalBiologicalBiological AssayBloodC-terminalCardiovascular DiseasesCardiovascular systemCatalytic DomainCause of DeathCell physiologyCellsCessation of lifeCharacteristicsCholesterolCholesterol HomeostasisClinical DataCodeComputer SimulationComputersCoronary ArteriosclerosisDataDatabasesDegradation PathwayDevelopmentDockingDrug CompoundingEducationEndopeptidasesEnsureEnvironmentEnzyme PrecursorsEventFamilial HypercholesterolemiaFoundationsGenesGeneticGoalsHeart DiseasesHumanImageryIndividualInterventionIntestinal AbsorptionLDL Cholesterol LipoproteinsLeadLengthLettersLinkLipidsLiverLow Density Lipoprotein ReceptorLow-Density LipoproteinsMediatingMethodsMolecularMusMutationNonsense MutationNumbersPatientsPeptide HydrolasesPeptidesPersonal SatisfactionPharmaceutical PreparationsPharmacotherapyPhasePlasmaPopulationProceduresProcessPropertyProtein PrecursorsProteinsPublic HealthPublishingRegulationResearch PersonnelResolutionRiskRisk FactorsScoreScreening procedureSingle Nucleotide PolymorphismSiteStructureSubtilisin Like Proprotein ConvertasesTestingWomanWorkZinc Compoundsbaseconceptcost effectivedrug marketexperiencegain of functionhypercholesterolemiain vitro Assaykexinlipid disorderloss of functionloss of function mutationmenmolecular modelingmortalitynovelpreventprogramssupercomputertherapeutic targetthree dimensional structurevirtualvirtual reality
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Heart disease is the leading cause of death for both men and women in the US, accounting for nearly 40% of all annual deaths. A high cholesterol level is a well-known risk factors for heart disease. Although blood cholesterol can be lowered using a number of marketed drugs, of which statins are the leading drugs, only 38% of patients taking these drugs are achieving the low-density lipoprotein cholesterol goals set by the National Cholesterol Education Program (NCEP). Furthermore, patients with homozygous familial hypercholesterolemia who have markedly elevated cholesterol levels respond poorly to current drug therapy, and are at very high risk of premature cardiovascular disease. These and other patients will dramatically benefit from an aggressive treatment of hypercholesterolemia. The long-term goal of this work is to develop novel drugs for cholesterol lowering. Our therapeutic target is the protease proprotein convertase subtilisin-like kexin type 9 (PCSK9). PCSK9 controls the degradation of the LDL receptor in the liver and thereby contributes to cholesterol homeostasis. PCSK9 is synthesized as a precursor protein that undergoes processing between the prodomain and catalytic domain. This processing is required for PCSK9 to be secreted and to undertake its biological activity. Our goal is to identify compounds that prevent the processing of PCSK9, thus prevent its secretion and its ability to participate in the degradation of the LDL receptor. To that end, we will integrate virtual (computer) screening methods and cell-based assays to identify lead compounds that can potentially be optimized to produce a cholesterol lowering drugs. Virtual screening, which requires the availability of atomic resolution 3D structures of the target protein, provides a cost effective way to screen million of compounds to identify just a few to be purchased and tested in a biological or biochemical assay. The specific aims of this work are to: 1) Use virtual screening methods to identify compounds that stabilize the PCSK9 zymogen and prevent its processing. 2) Determine the ability of the selected compounds to stabilize the PCSK9 zymogen and prevent its processing in an in vitro assay. PUBLIC HEALTH RELEVANCE: Heart disease is the leading cause of death for both men and women in the US. A high cholesterol level is well-known risk factors for heart disease. Although blood cholesterol can be lowered using a number of marketed drugs, these drugs do not treat a segment of the population having very high cholesterol. Our goal is to develop new cholesterol lowering drugs that could have an effect on all individuals with high cholesterol levels, including that segment of the population having very high cholesterol.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structure-Based Search for Novel Antihypercholestrolemic Agent
-
批准号:7909109
-
项目类别:
-
资助金额:$68.13万
-
财政年份:2008
-
负责人:Sherin S Abdel-Meguid
-
依托单位:
Structure-Based Search for Novel Antihypercholestrolemic Agent
-
批准号:8066009
-
项目类别:
-
资助金额:$65.53万
-
财政年份:2008
-
负责人:Sherin S Abdel-Meguid
-
依托单位:
Search for Antithrombotic Compounds to Overcome Adverse Effects of Current Drugs
-
批准号:7481477
-
项目类别:
-
资助金额:$25.63万
-
财政年份:2008
-
负责人:Sherin S Abdel-Meguid
-
依托单位:
Search for Anti-Androgen Compounds to Overcome Resistance of Current Drugs
-
批准号:7154608
-
项目类别:
-
资助金额:$24.18万
-
财政年份:2006
-
负责人:Sherin S Abdel-Meguid
-
依托单位:
海外基金